Needham lowered the firm’s price target on Staar Surgical to $52 from $54 but keeps a Buy rating on the shares after the company provided its medium-term targets in its Investor Day presentation yesterday. The expected growth through 2026 is in line with recent commentary, but the operating margin guidance of 12%-16% expected in 2026 was slightly below expectations, the analyst tells investors in a research note. The firm adds however that with Staar’s next-12 month enterprise value to expected sales multiple near five-year lows, the stock’s valuation looks “attractive”.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STAA:
- Staar Surgical price target lowered to $45 from $50 at Piper Sandler
- Staar Surgical downgraded to Hold from Buy at Benchmark
- Staar Surgical sees FY26 sales $500M-$550M, operating margin of 12%-16%
- Staar Surgical to replace Urstadt Biddle in S&P 600 at open on 8/22
- Dolby to replace Staar Surgical in S&P 400 at open on 8/22